Closing arguments are set to begin in Arkansas' billion-dollar lawsuit against a Johnson & Johnson subsidiary that makes the antipsychotic drug Risperdal.
Closing arguments set in J&J Risperdal trial
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.